% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • lextan1 lextan1 Jun 23, 2014 10:10 AM Flag

    HUGE volume

    Almost 1M shares traded in the first 40 minutes. Someone is accumulating.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The best thing about this stock is that this message board is quiet so this has plenty of room to room. FV right now is probably $10-$15. Any good news and its double that.

    • probably shorts exiting, stock is dead money unless someone wants their cash and technology. I would not expect much premium even if they do a deal. All IMO, not advice.

      • 1 Reply to bioimmunomabman
      • "not expect much premium even if they do a deal". ECYT set bar for NSCLC 2b so high, reaching primary end point itself is big thing. PFS 7.1 months vs PFS 3.5months (most recent Eli lilly study). For endocyte OS will be in range of 13 to 15 monts. OS for Docetaxel alone is 9.1 months, recent Eli lilly improved OS to 10.1 months in Phase-III study.
        See below Data for Eli lilly drug. There are no drugs even little closer to Endocyte. I would easily expect full sponsorship of Phase-3 trial of NSCLC and around two to three hundred m payment with Royalty.

        Patients treated on the CYRAMZA-plus-docetaxel arm (n=628) achieved a median OS of 10.5 months compared to 9.1 months for patients on the placebo-plus-docetaxel arm (n=625). The OS hazard ratio was 0.86 (95% CI, 0.751-0.979, p=0.023), which corresponds to a 14 percent reduction in risk of death.

        Median PFS was 4.5 months on the CYRAMZA-plus-docetaxel arm compared to 3.0 months on the placebo-plus-docetaxel arm, with a PFS hazard ratio of 0.76 (p

5.215-0.085(-1.60%)10:28 AMEDT